Long-Term Follow-Up of Ninety Eight Iranian Patients With Primary Immune Deficiency in a Single Tertiary Centre Publisher Pubmed



Nabavi M¹ ; Arshi S¹ ; Bemanian MH¹ ; Aghamohammadi A² ; Mansouri D³ ; Hedayat M⁴ ; Nateghian A⁵ ; Noorbakhsh S⁶ ; Ehsanipour F⁶ ; Faranoush M⁷ ; Shakeri R⁸ ; Mesdaghi M⁹ ; Taghvaei B¹ ; Ghalebaghi B^{1, 10} Show All Authors
Source: Allergologia et Immunopathologia Published:2016

Abstract

Purpose The aim was to describe the clinical manifestations, complications and long-term outcome of a cohort of Iranian patients with primary immune deficiency (PID). Method We retrospectively studied the demographic, clinical and immunological characteristics of the PID patients in a single tertiary centre, from January 1989 to July 2014. The patients were classified according to the International Union of Immunological Societies Expert Committee on PID. Results 98 patients were diagnosed with and followed-up for 15 disorders. The mean age at onset and diagnosis and the diagnostic delay were 8 ± 10, 14.2 ± 13.1 and 6.1 ± 7 years, respectively. Parental consanguinity rate was 57%. Predominantly Antibody Deficiency was the most common diagnosis (n = 63), followed by congenital defects of phagocytes (n = 16), combined immunodeficiencies (n = 12), well defined syndromes (n = 4) and defects in innate immunity (n = 3). Recurrent sinopulmonary infection was the most common presentation. Active infections were treated appropriately, in addition to prophylactic therapy with IVIG and antimicrobials. Not all the patients were compliant with prophylactic regimens due to cost and unavailability. One SCID patient underwent successful bone marrow transplantation. The total mortality rate was 19% during the follow-up period (7.8 ± 7.6 years). The mean age of living patients at the time of study was 23 ± 11.7 years. Conclusions Physicians awareness of PID has been rising dramatically in Iran, ensuring an increasing number of patients being diagnosed and treated. More effective treatment services, including health insurance coverage and drug availability are needed to improve the outcome of PID patients. © 2016 SEICAP